Central nervous system relapse in patients with breast cancer is associated with advanced stages, with the presence of circulating occult tumor cells and with the HER2/neu status

Breast Cancer Research

Volumn 8, Issue 4, 2006, Pages

  Souglakos, John ^a   Vamvakas, Lambros ^a   Apostolaki, Stella ^b   Perraki, Maria ^b   Saridaki, Zacharenia ^a   Kazakou, Irine ^a   Pallis, Athanasios ^a   Kouroussis, Charalambos ^a   Androulakis, Nikos ^a   Kalbakis, Kostas ^a   Millaki, Georgia ^a   Mavroudis, Dimitris ^a   Georgoulias, Vassilis ^a  

^a UNIVERSITY HOSPITAL OF HERAKLION   (Greece)

^b UNIVERSITY OF CRETE   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKERATIN 19; EPIDERMAL GROWTH FACTOR RECEPTOR 2; MESSENGER RNA; TAXANE DERIVATIVE; ANTINEOPLASTIC AGENT; TAXOID;

ADULT; ADVANCED CANCER; AGED; ARTICLE; BREAST CANCER; CANCER INCIDENCE; CANCER STAGING; CENTRAL NERVOUS SYSTEM METASTASIS; CONFIDENCE INTERVAL; CONTROLLED STUDY; FEMALE; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MEDICAL RECORD; MULTIVARIATE ANALYSIS; PREDICTION; REAL TIME POLYMERASE CHAIN REACTION; RISK ASSESSMENT; SOLID TUMOR; TUMOR CELL; BIOSYNTHESIS; BREAST NEOPLASMS; CENTRAL NERVOUS SYSTEM TUMOR; MIDDLE AGED; PATHOLOGY; PATHOPHYSIOLOGY; PREDICTIVE VALUE; SECONDARY; TUMOR EMBOLISM; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CENTRAL NERVOUS SYSTEM NEOPLASMS; FEMALE; HUMANS; KERATIN-19; MIDDLE AGED; NEOPLASM STAGING; NEOPLASTIC CELLS, CIRCULATING; PREDICTIVE VALUE OF TESTS; RECEPTOR, ERBB-2; RNA, MESSENGER; TAXOIDS;

EID: 33745938527     PISSN: 1465542X     EISSN: 1465542X     Source Type: Journal    
DOI: 10.1186/bcr1516     Document Type: Article

References (30)

1. Jemal A, Thomas A, Murray T, Thum M: Cancer Statistics, 2002. CA Cancer J Clin 2002, 52:23-47.
2. Di Stefano A, Yap HY, Hortobagyi GN, Blumenschein GR: The natural history of breast cancer patients with brain metastases. Cancer 1979, 44:1913-1918.
3. Tsukuda Y, Fouad A, Pickren JW, Lane WW: Central nervous system metastases from breast carcinoma: autopsy study. Cancer 1983, 52:2349-2354.
4. Posner JB, Chernik NI: Intracranial metastases from systemic cancer. Adv Neurol 1978, 19:579-591.
5. Samaan NA, Buzdar AU, Aldinger KA, Schultz PN, Yang KP, Romsdahl MM, Martin R: Estrogen receptor: a prognostic factor in breast cancer. Cancer 1981, 47:554-560.
6. Stewart JF, King RJ, Sexton SA, Millis RR, Rubens RD, Hayward JL: Oestrogen receptors, sites of metastatic disease and survival in recurrent breast cancer. Eur J Cancer 1981, 17:449-453.
7. Bendell JC, Domchek SM, Burstein HJ, Harris L, Younger J, Kuter I, Bunnell C, Rue M, Gelman R, Winer E: Central nervous system metastatses in women who receive trastuzumab-based therapy for metastatic breast carcinoma. Cancer 2003, 97:2972-2977.
8. Miller KD, Weathers T, Haney LG, Timmerman R, Dickler M, Shen J, Sledge GW Jr: Occult central nervous system involvement in patients with metastatic breast cancer: prevalence, predictive factors and impact on overall survival. Ann Oncol 2003, 14:1072-1077.
9. Crivellari D, Pagani O, Veronesi A, Lombardi D, Nole F, Thurlimann B, Hess D, Borner M, Bauer J, Martinelli G, International Breast Cancer Study Group, et al.: International Breast Cancer Study Group. High incidence of central nervous system involvement in patients with metastatic or locally advanced breast cancer treated with epirubicin and docetaxel. Ann Oncol 2001, 12:353-356.
10. Slimane K, Andre F, Delaloge S, Dunant A, Perez A, Grenier J, Massard C, Spielmann M: Risk factors for brain relapse in patients with metastatic breast cancer. Ann Oncol 2004, 15:1640-1644.
11. Freilich RJ, Seidman AD, De Angelis LM: Central nervous system progression of metastatic breast cancer in patients treated with paclitaxel. Cancer 1995, 76:232-236.
12. Eiseman JL, Eddington ND, Leslie J, MacAuley C, Sentz DL, Zuhowski M, Kujawa JM, Young D, Egorin MJ: Plasma pharmacokinetics and tissue distribution of paclitaxel in CD2F1 mice. Cancer Chemother Pharmacol 1994, 34:465-471.
13. Heimans JJ, Vermorken JB, Wolbers JG, Eeltink CM, Meijer OW, Taphoorn MJ, Beijnen JH: Paclitaxel (Taxol) concentrations in brain tumor tissue. Ann Oncol 1994, 5:951-953.
14. Lesser GJ, Grossman SA, Eller S, EK Rowinsky: Distribution of 3H-taxol in the nervous system (NS) and organs of rats [abstract]. Proc Am Soc Clic Oncol 1993, 12:160.
15. Fellner S, Bauer B, Miller DS, Schaffrik M, Fankhanel M, Spruss T, Bernhardt G, Graeff C, Farber L, Gschaidmeier H, et al.: Transport of paclitaxel (Taxol) across the blood-brain barrier in vitro and in vivo. J Clin Invest 2002, 110:1309-1318.
16. Stathopoulou A, Gizi A, Perraki M, Apostolaki S, Malamos N, Mavroudis D, Georgoulias V, Lianidou ES: Real-time quantification of CK-19 mRNA-positive cells in peripheral blood of breast cancer patients using the lightcycler system. Clin Cancer Res 2003, 9:5145-5151.
17. Stathopoulou A, Vlachonicolis I, Mavroudis D, Perraki M, Kouroussis Ch, Apostolaki S, Malamos N, Kakolyris S, Kotsakis A, Xenidis N, et al.: Molecular detection of cytokeratin-19-positive cells in the peripheral blood of patients with operable breast cancer: Evaluation of their prognostic significance. J Clin Oncol 2002, 20:3404-3412.
18. Kaplan EL, Meier P: Non-parametric estimation from incomplete observations. J Am Stat Assoc 1959, 53:457-481.
19. Lower EE, Blau R, Bismayer J, Hawkins HH, Baughman RP: Increased brain metastasis detected in metastatic breast cancer patients receiving herceptin [abstract]. Breast Cancer Res Treat 2001, 69:357.
20. Clayton AJ, Danson S, Jolly S, Ryder WD, Burt PA, Stewart AL, Wilkinson PM, Welch RS, Magee B, Wilson G, et al.: Incidence of cerebral metastases in patients treated with trastuzumab for metastatic breast cancer. Br J Cancer 2004, 91:639-643.
21. Fuchs IB, Loebbecke M, Buhler H, Stoltenburg-Didinger G, Heine B, Lichtenegger W, Schaller G: HER2 in brain metastases: issues of concordance, survival and treatment. J Clin Oncol 2002, 20:4130-4133.
22. Burstein HJ, Lieberman G, Slamon DJ, Winer EP, Klein P: Isolated central nervous system metastases in patients with HER2-overexpressing advanced breast cancer treated with first-line trastuzumab-based therapy. Ann Oncol 2005, 16:1772-1777.
23. Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, Fleming T, Eiermann W, Wolter J, Pegram M, et al.: Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001, 344:783-792.
24. Xenidis N, Vlachonicolis I, Mavroudis D, Perraki M, Stathopoulou A, Malamos N, Kouroussis C, Kakolyris S, Apostolaki S, Vardakis N, et al.: Peripheral blood circulating cytokeratin-19 mRNA-positive cells after the completion of adjuvant chemotherapy in patients with operable breast cancer. Ann Oncol 2003, 14:849-855.
25. Braun S, Pantel K, Muller P, Janni W, Hepp F, Kentenich CR, Gastroph S, Wischnik A, Dimpfl T, Kindermann G, et al.: Cytokeratinpositive cells in the bone marrow and survival of patients with stage I, II, or III breast cancer. N Engl J Med 2000, 342:525-533.
26. Pantel K, Cote RJ, Fodstad O: Detection and clinical importance of micrometastatic disease. J Natl Cancer Inst 1999, 91:1113-1124.
27. Fidler IJ, Yano S, Zhang RD, Fujimaki T, Bucana CD: The seed and soil hypothesis: vascularization and brain metastases. Lancet Oncol 2002, 3:53-57.
28. Maguire D, O'Sullivan GC, McNamara B, Collins JK, Shanahan F: Bone-marrow micrometastases in patients with brain metastases from epithelial cell tumors. QJM 2000, 93:611-615.
29. Zgang RD: The biology and mechanisms of chemoresistance in brain metastases. Diss Abstr Int B 1995, 56:4108-16.
30. Bozionellou V, Mavroudis D, Perraki M, Papadopoulos S, Apostolaki S, Stathopoulos E, Stathopoulou A, Lianidou E, Georgoulias V: Transtuzumab administration can effectively target chemotherapy-resistant cytokerratin-19 messager-RNA-positive tumor cells in the peripheral blood and bone marrow of patients with breast cancer. Clin Cancer Res 2004, 10:8185-8194.